Wyeth

Elan Pharmaceuticals, Inc.

Biogen Ma Inc.

Janssen Sciences Ireland Uc

Janssen Alzheimer Immunotherapy

Biogen, Incorporated

Biogen Idec Ma Inc.

Ivan Lieberburg

James Callaway

Michael Grundman

Lioudmila Tchistiakova

Davinder Gill

Angela Widom

Jack Steven Jacobsen

Elizabeth Messersmith

Lars Ekman

Keith M Gregg

Ronald Black

Andrei William Konradi

Michael A Pleiss

Theodore A Yednock

Wagner Marcelo Zago

Stephen B Freedman

George Shopp

Manuel J Buttini

Gene G Kinney

Jim Callaway

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.

Methods of treating inflammatory and autoimmune diseases with natalizumab

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.

Immunotherapy regimes dependent on ApoE status

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.

Use of tau to monitor immunotherapy

The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A&#x3b2;. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment.

Treatment of amyloidogenic diseases

The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A&#x3b2;. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment.

Alpha 4 inhibitors are used in treatment of inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, rheumatoid arthritis and asthma. Rare occurrences of progressive multifocal leucoencephalopathy during treatment with an alpha-4 agent suggest the possibility that it may be related to such treatment. Monitoring for the JC virus and educating caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of alpha 4 inhibitor therapy.

Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds

The application relates to a method of using compositions having anti-alpha-4 integrin and/or anti-alpha-9 integrin activity to inhibit liquid tumor growth, malignancies thereof and/or development of metastases thereof that involve expression of an alpha-4 integrin and/or alpha-9 integrin. Pharmaceutical compositions and combination therapies (for example, with chemotherapies) for the inhibition of liquid tumor growth, malignancies thereof and/or development of metastases thereof are also provided.

Methods and compositions for treating liquid tumors

This application relates to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to alpha-4 integrin or an immunologically active antigen binding fragment in therapeutically effective amounts. The application also relates generally to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and small molecule alpha-4 integrin antagonist that inhibits the alpha-4 integrin (&#x3b1;4 integrin) interaction with VCAM-1. The invention further relates to methods of preparing the compounds and methods of using the compounds and compositions.

Methods and compositions for treating rheumatoid arthritis

Growing community of inventors

Berkeley, CA, United States of America

Ivan Lieberburg